Binge eating disorder is strongly associated with weight gain and obesity, though not all individuals with obesity have BED.

GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in adults with type 2 diabetes and obesity, new data show.

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

A groundbreaking study has revealed that GLP-1 receptor agonists—including popular weight-loss and diabetes drugs like ...

With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...

An investigation has found at least 74 complaints have been made to hospital managers across England in the past 12 months.

A new study has found that a drug used for treating obesity and type 2 diabetes may also help slow the growth of breast cancer caused by obesity.

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

The researchers estimate 6.5 billion years of life will likely be lost globally due to premature deaths caused by obesity’s negative health effects. The weight loss drugs could lead to a disruptive ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

A new study has found that an anti-obesity drug called tirzepatide, which is sold under the names Mounjaro for diabetes and ...